Scandinavian ChemoTech signs its first European distribution agreement with Lee Imaging Ukraine LLC

Today ChemoTech signed a distribution agreement with Lee Imaging Ukraine LLC (Lee Imaging). The agreement with Lee Imaging includes a smaller study together with a government medical university hospital and an order worth a minimum of EUR 30,000.

Lee Imaging is a company that was established in the Ukraine, the largest country in eastern Europe, in 2012 and is owned 100% by foreign investors as it’s a fully owned subsidiary of Lee Imaging International LLC in the USA. The group operates more than 60 MRI CT centres in USA, Canada and Mexico.

The clinical study will include patients that suffers from breast cancer, that is inoperable, with the objective to study: the efficacy and safety of the D-EECT Protocol for treating inoperable breast cancer tumours.

For Lee Imaging to be able to receive the commercial license for IQwave™ it is mandatory for ChemoTech to secure the CE-mark of IQwave™.

“It feels promising to sign an agreement with a group with such a wide and long experience from working in business development with complex medical devices. Their success shows that they are able to work with long term strategies, something that is of great importance when establishing a new therapy” - says Mohan Frick, CEO

“We have the intent to study the efficacy and safety of the new electroporation technology, developed by ChemoTech, when treating breast cancer patients. In the future the use of the ChemoTechs Tumour Specific Electroporation therapy method will be extended to some types of solid malignant tumours of the skin and visceral organs.” - says Prof. Kovalyov Olexi Vice President of Lee Imaging Ukraine LLC.


Svensk text:

Scandinavian ChemoTech tecknar sitt första europeiska distributionsavtal med Lee Imaging Ukraine LLC

Idag tecknade ChemoTech ett distributionsavtal med Lee Imaging Ukraine LLC (Lee Imaging). Avtalet med Lee Imaging inkluderar en mindre studie tillsammans med ett statligt medicinskt universitetssjukhus och en order värd minst 30 000 euro.          

Lee Imaging är ett företag som grundades i Ukraina, det största landet i Östeuropa, 2012 och ägs 100% av utländska investerare eftersom det är ett helägt dotterbolag till Lee Imaging International LLC i USA. Gruppen driver mer än 60 MRT-centra i USA, Kanada och Mexiko.

Den kliniska studien kommer att inkludera patienter som lider av inoperabel bröstcancer med syftet att studera: effektiviteten och säkerheten av D-EECT-protokollet för behandling av inoperabla bröstcancertumörer.

För att Lee Imaging ska få den kommersiella licensen för IQwave ™ är det obligatoriskt för ChemoTech att säkra CE-märkningen av IQwave ™.

”Det känns lovande att teckna ett avtal med en grupp som har en sådan bred och lång erfarenhet från att arbeta med affärsutveckling av komplex medicinsk utrustning. Deras framgång visar att de kan arbeta med långsiktiga strategier, något som är av stor betydelse när man etablerar en ny terapi ”- säger Mohan Frick, VD

”Vi har för avsikt att studera effektiviteten och säkerheten av den nya elektroporationsstekniken, utvecklad av ChemoTech, vid behandling av bröstcancerpatienter. I framtiden kommer användningen av ChemoTechs tumörspecifika elektroporation att utvidgas till att omfatta vissa typer av fasta maligna tumörer i huden och viscerala organ. " - säger professor Kovalyov Olexi vice president för Lee Imaging Ukraine LLC.

For more information, please contact:

Mohan Frick, Co-Founder and CEO

Phone: +46 (0)10-218 93 00

info@chemotech.se

Certified Adviser: Västra Hamnen Corporate Finance AB, Tel: +46 40 200 250, E-mail: ca@vhcorp.se

This information is such information which Scandinavian ChemoTech AB (publ) are obligated to make public according to EU’s market abuse regulation and the law of securities market. The information was submitted by the agency of above stated contact person, to be made public on Friday April 17th 2019 at 09.00 (CET).

Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, tumour specific electroporation, available for treatment of both for humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where tumour specific electroporation can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Västra Hamnen Corporate Finance AB is the company's Certified Adviser. Read more at: www.chemotech.se.

Subscribe